APA (7th ed.) Citation

P, B., C, C. N., A, C., H, M. H., L, C., M, B., . . . C, J. (2016). Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope. Oncoimmunology, 5(10), e1216290. https://doi.org/10.1080/2162402X.2016.1216290

Chicago Style (17th ed.) Citation

P, Baumgaertner, et al. "Vaccination of Stage III/IV Melanoma Patients with Long NY-ESO-1 Peptide and CpG-B Elicits Robust CD8+ and CD4+ T-cell Responses with Multiple Specificities Including a Novel DR7-restricted Epitope." Oncoimmunology 5, no. 10 (2016): e1216290. https://doi.org/10.1080/2162402X.2016.1216290.

MLA (9th ed.) Citation

P, Baumgaertner, et al. "Vaccination of Stage III/IV Melanoma Patients with Long NY-ESO-1 Peptide and CpG-B Elicits Robust CD8+ and CD4+ T-cell Responses with Multiple Specificities Including a Novel DR7-restricted Epitope." Oncoimmunology, vol. 5, no. 10, 2016, p. e1216290, https://doi.org/10.1080/2162402X.2016.1216290.